The Company is seeking withdrawal of the Registration Statement because of unfavorable market conditions. To that end, HART will not proceed with its planned initial public offering of its common stock. Instead, HBIO will proceed with the spin-off of HART promptly following the effectiveness of a Registration Statement on Form 10 to be filed by HART with the SEC to become a public reporting company. Harvard Bioscience expects the shares of HART common stock distributed in the spin-off to be publically tradeable, subject to compliance with applicable securities laws. HART intends to withdraw its Registration Statement on Form S-1 filed with the SEC and thereafter file the Registration Statement on Form 10 under the Securities Exchange Act of 1934.
Harvard Bioscience intends to effect the separation of its regenerative medicine business through the spin-off of 100% of HART's common stock to Harvard Bioscience stockholders in a pro-rata, tax-free dividend. Prior to such spin-off, Harvard Bioscience plans to contribute $15 million in cash to fund HART's initial operations. Harvard Bioscience also intends to apply to list HART's common stock on the NASDAQ Capital Market under the symbol "HART" in connection with the spin-off and related Form 10 filing
Recent HBIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:02:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:02:24 PM
- Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024 • GlobeNewswire Inc. • 06/06/2024 08:05:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/29/2024 09:01:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:24:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:23:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:22:21 PM
- Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024 • GlobeNewswire Inc. • 05/23/2024 08:05:00 PM
- Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference • GlobeNewswire Inc. • 05/16/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 09:20:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 09:00:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:00:39 AM
- Harvard Bioscience Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/07/2024 11:00:00 AM
- Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET • GlobeNewswire Inc. • 04/29/2024 12:45:00 PM
- Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth • GlobeNewswire Inc. • 04/09/2024 01:00:00 PM
- Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti’s Small Cap Conference and KeyBanc’s Life Sciences & MedTech Conference • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 10:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:04:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:03:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 12:00:19 PM
- Harvard Bioscience Announces Fourth Quarter 2023 Financial Results • GlobeNewswire Inc. • 03/07/2024 12:00:00 PM
- Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting • GlobeNewswire Inc. • 03/06/2024 01:30:00 PM
- Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET • GlobeNewswire Inc. • 02/27/2024 10:10:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:05:25 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:00:05 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM